Revance will pay up to $25m to regain botox rights from Medicis
This article was originally published in Scrip
Executive Summary
After Revance Therapeutics got to the end of Phase II for RT001 – its botulinum toxin type A gel to reduce crow's feet – the private company sued its partner when the Valeant Pharmaceuticals acquisition target Medicis Pharmaceutical disagreed about whether it was now obligated to make a decision about taking the program into Phase III.